Vaginal Dryness Treatment Online in California (GSM / Vaginal Atrophy)

Yes. California Business and Professions Code Section 2290.5 permits California-licensed physicians to evaluate and treat genitourinary syndrome of menopause (GSM) by synchronous video visit. The Medical Board of California holds telehealth physicians to the same standard of care as in-person physicians. Per ACOG Practice Bulletin 141 and NAMS, low-dose topical vaginal estrogen is the most effective treatment for GSM and can be prescribed via telehealth for postmenopausal women without contraindications. Non-hormonal options — ospemifene, vaginal DHEA, OTC moisturizers — are also available. Self pay is $79. Aetna is in-network as of April 30, 2026.

GSM is a collection of symptoms caused by declining estrogen levels in menopause, surgical menopause (oophorectomy), or other estrogen-depleting conditions. Per the American College of Obstetricians and Gynecologists (ACOG), GSM affects up to 50% of postmenopausal women. Symptoms include vaginal dryness, burning, irritation, dyspareunia (painful intercourse), urinary urgency, and recurrent UTIs. Unlike vasomotor symptoms such as hot flashes that often resolve over time, GSM is a progressive condition that worsens without treatment.

Yes, for most women. Low-dose vaginal estrogen — such as estradiol cream 0.01% or estradiol ring/tablet — is considered safe for most postmenopausal women because systemic absorption is minimal at therapeutic doses, per ACOG and NAMS. Women with a history of hormone-sensitive breast cancer should discuss treatment options with their oncologist before starting any estrogen preparation. The FDA has approved low-dose vaginal estrogen for this indication. TeleDirectMD reviews contraindications at every visit and refers to OB/GYN or oncology when needed.

GSM affects an estimated 50% of postmenopausal women per ACOG Practice Bulletin 141. California has approximately 6 million women aged 50 and over, suggesting that up to 3 million California women may experience GSM symptoms. Despite this high prevalence, surveys by the North American Menopause Society indicate that fewer than 25% of affected women seek treatment — often because symptoms are attributed to inevitable aging. Effective treatments are available and have been shown to improve quality of life, sexual function, and urinary symptoms.

Per ACOG and NAMS, first-line treatments include: low-dose vaginal estradiol cream 0.01% (GoodRx approximately $34/tube at goodrx.com); ospemifene 60 mg oral (Osphena, approximately $200–$350/month); vaginal DHEA/prasterone (Intrarosa, approximately $250–$400/month); and OTC vaginal moisturizers such as Replens (approximately $15–$30 OTC). Prescription costs at the pharmacy are separate from the TeleDirectMD visit fee of $79 self-pay.

Yes. GSM-related changes — thinning and increased fragility of vaginal and urethral tissue, elevated vaginal pH above 5.0, and reduced Lactobacillus flora — significantly increase susceptibility to urinary tract infections in postmenopausal women. ACOG recognizes recurrent UTIs as part of the GSM spectrum. Low-dose vaginal estrogen has been shown to reduce recurrent UTI frequency in postmenopausal women by restoring protective vaginal flora.

Yes, for in-network commercial plans. California Insurance Code §10123.85 (AB 744, 2019) requires commercial health plans to reimburse telehealth on the same basis as in-person services when TeleDirectMD is in-network. Aetna became in-network effective April 30, 2026. UnitedHealthcare Commercial was approved effective May 29, 2026, covering commercial plans and Medicare Advantage. Medi-Cal and Kaiser Permanente are not participating.

Aetna became in-network for TeleDirectMD in California effective April 30, 2026. Aetna commercial plan members may be able to use in-network benefits. Always verify plan eligibility directly with Aetna before your visit. Self pay ($79) is available regardless of insurance status.

TeleDirectMD is not currently enrolled as a Medi-Cal rendering provider. If you have Medi-Cal, you can use the $79 self-pay option or find a Medi-Cal-enrolled provider through your managed care plan or the California DHCS directory at dhcs.ca.gov. Planned Parenthood California and California Family PACT offer free or low-cost reproductive health care for eligible Californians.

Seek in-person evaluation if you have abnormal uterine bleeding (which must be evaluated before starting any estrogen); vaginal lesions or masses of uncertain origin; a history of hormone-sensitive breast cancer requiring oncology input; symptoms that have not responded to OTC vaginal moisturizers; or if you are uncertain whether your symptoms stem from menopause rather than another cause. Planned Parenthood California and OB/GYN practices statewide provide in-person GSM evaluation.

Yes. For women who cannot or prefer not to use estrogen, non-hormonal options endorsed by NAMS include: OTC vaginal moisturizers (Replens, HydroGel) applied regularly; vaginal lubricants used during intercourse; ospemifene (Osphena) — an oral SERM that is estrogen-free and FDA-approved for GSM-related dyspareunia; and vaginal DHEA (prasterone/Intrarosa), which works locally without raising systemic estrogen levels. These options can be discussed and prescribed at a TeleDirectMD video visit.

California requires all prescriptions to be issued electronically under Assembly Bill 2789 (effective January 1, 2022), per the Medical Board of California. If a prescription is appropriate, TeleDirectMD sends an e-prescription electronically to your chosen California pharmacy — CVS, Walgreens, Rite Aid, Walmart, Safeway — during or immediately after your visit. Most California pharmacies fill prescriptions within one to four hours. The $79 self-pay visit fee is separate from any pharmacy prescription costs.